CRS-HIPEC for Peritoneal Mesothelioma: 53-Month Median Survival and 47% Five-Year Rate
David Foster
February 26, 2026
CRS-HIPEC (cytoreductive surgery + hyperthermic chemotherapy) achieves 53-month median survival and 47% five-year survival for peritoneal mesothelioma patients. Learn candidacy, outcomes, and leading treatment centers.